XPO1 and cancer: The anti-cancer effects of CRM1 inhibitors are based on the induction of cell death by apoptosis and on cell cycle arrest due to activation of the transcriptional programs of tumor suppressor genes, such as TP53, RB1, and FOXO-related tumor suppressors [26, 27, 32].